Emergent BioSolutions Inc

Company Snapshot
400 Professional Drive
Gaithersburg, MD 20879
United States
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 2,500
https://www.emergentbiosolutions.com
Please select from the dropdown
Company Financials

2020
2021
2022
Gross Profit
$1,031,400,000
$1,035,200,000
$427,200,000
Operating Income
$433,800,000
$394,300,000
($166,000,000)
Net Income
$305,100,000
$230,900,000
($223,800,000)
2020
Gross Profit
$1,031,400,000
Operating Income
$433,800,000
Net Income
$305,100,000
2021
Gross Profit
$1,035,200,000
Operating Income
$394,300,000
Net Income
$230,900,000
2022
Gross Profit
$427,200,000
Operating Income
($166,000,000)
Net Income
($223,800,000)
The above data on Emergent BioSolutions Inc came from annual proxy statements to the SEC. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov
Top Executives
Total Cash info
Equity info
Other info
Total Compensation
Top Executives
Total Compensation
Robert Kramer
Director, President and Chief Executive Officer
$1,340,375
$6,231,882
$6,316
$7,578,573
Robert Kramer
$7,578,573
Director, President and Chief Executive Officer
Adam Havey
Executive Vice President and Chief Operating Officer
$747,616
$2,866,185
$7,825
$3,621,626
Adam Havey
$3,621,626
Executive Vice President and Chief Operating Officer
Richard Lindahl
Principal Accounting Officer, Executive Vice President Chief Financial Officer and Treasurer
$790,228
$2,723,385
$9,150
$3,522,763
Richard Lindahl
$3,522,763
Principal Accounting Officer, Executive Vice President Chief Financial Officer and Treasurer
Atul Saran
Executive Vice President Corporate Development, General Counsel and Corporate Secretary
$773,221
$2,723,385
$8,262
$3,504,868
Atul Saran
$3,504,868
Executive Vice President Corporate Development, General Counsel and Corporate Secretary
Jennifer Fox
Senior Vice President Legal Affairs and Deputy General Counsel
$666,594
$2,247,463
$9,150
$2,923,207
Jennifer Fox
$2,923,207
Senior Vice President Legal Affairs and Deputy General Counsel
Emergent BioSolutions Inc listed the above executives on its annual proxy statement to the SEC for the fiscal year of 2022. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov

The sum of all cash payments made to an individual for services during a given year. It is comprised of yearly Base Pay and Bonuses

To view more detailed proxy data including previous years contact our sales team.

Contact Us

The value of stock and option awards plus long term incentives granted.

To view more detailed proxy data including previous years contact our sales team.

Contact Us

This covers all compensation that don't fit in any of these other standard categories

To view more detailed proxy data including previous years contact our sales team.

Contact Us